What FB Dermatology does

FB Dermatology s.r.l. is an Italian-headquartered biotech company founded in 2014 as part of the FB Research Group pharmaceutical holding. The company develops and markets proprietary medical devices and consumable gels built around its patented Fluorescent Light Energy (FLE) platform, in which chromophores in a photoconverter gel convert LED light into fluorescent energy that stimulates the skin's own cellular repair mechanisms. Its commercial portfolio is organised into three brands: Kleresca for therapeutic dermatology (acne, rosacea, skin rejuvenation), Lumixa for aesthetic medicine (skin normalising and collagen boosting), and LumiHeal for wound care using Fluorescence Biomodulation, which carries CE mark in Europe. A fourth line, Dermohemp (CBD-based treatments for atopic dermatitis), is listed as forthcoming.

The company sells exclusively through a B2B partner-clinic model rather than direct to consumers. Hardware (LED devices such as the Kleresca Light and LumiHeal Activator) and recurring consumables (photoconverter gels and Light Absorbing Molecule gels) are purchased by dermatology clinics, aesthetic practices, hospitals, and wound care centres that administer treatments to patients. Sales are supported by a field engagement motion targeting clinic decision-makers, a PartnerNet portal for clinic partners, and the FB Academy clinical education programme for healthcare professionals.

FB Dermatology operates across approximately 15 countries spanning Europe (Austria, Belgium, Switzerland, Czech Republic, Germany, Denmark, Spain, France, the UK, Italy, Luxembourg, the Netherlands, Portugal), the Middle East (Israel), and Oceania (Australia and New Zealand), with named partner clinics including enterprise chains such as Laser Clinics Australia and Laser Clinics New Zealand alongside independent specialty clinics. Pricing is not publicly disclosed and is set by individual partner clinics for end patients. No external venture or private equity funding rounds are disclosed, with capital and strategic direction provided by parent FB Research Group.

Name

FB Dermatology

Legal name

FB DERMATOLOGY s.r.l.

Website

https://fb-dermatology.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

FB Dermatology is an Italian biotech company that develops and sells proprietary FLE (Fluorescent Light Energy) medical devices and gel consumables through dermatology, aesthetic, and wound care clinics across Europe, Israel, Australia, and New Zealand.

Ownership category

akta.pro rank

Product category

Medical Dermatology Treatment Systems

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Laser & Energy-Based Dermatology (HLAKACAF)

akta.pro secondary industries

Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI), LED Light Therapy Treatments (HSALADAJ), Professional Skincare & Facial Treatments (CRABALAF)

Keywords

• Fluorescent light energy
• Dermatology treatment systems
• Photobiomodulation therapy
• Wound care devices
• Medical aesthetic systems

Headquarters

HQ city

San Benedetto Del Tronto

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Kleresca Treatment Systems: FB Dermatology provides its proprietary FLE technology systems (Kleresca Light device + photoconverter gels) to partner clinics for treating patients with acne, rosacea, and skin rejuvenation. Clinics purchase the treatment systems and consumable gels to administer treatments to patients.
2. LumiHeal Wound Care Products: Sale of LumiHeal System including LED Activator devices and LAM (Light Absorbing Molecule) topical gel for wound care treatment in hospitals, clinics, and home care settings. Features both hospital/clinic LED Activator and portable handheld version.
3. Lumixa Aesthetic Treatments: Lumixa phototherapy system and associated gel products for aesthetic conditions including skin normalising and collagen boosting treatments in aesthetic clinics.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

FB Dermatology develops and sells patented Fluorescent Light Energy (FLE) treatment systems for dermatology, aesthetics, and wound care. Its core offerings include the Kleresca brand (LED light device plus photoconverter gel for acne, rosacea, and skin rejuvenation), the Lumixa brand (phototherapy system for aesthetic indications), and the LumiHeal system (LED activator plus Light Absorbing Molecule gel for chronic and acute wounds). Products are sold B2B to licensed clinics and healthcare providers who administer treatments to patients.

Product overview

FB Dermatology is a biotech company offering innovative and exclusive patented solutions for tissue regeneration, dermatology conditions, and aesthetic alterations. The product portfolio is organized around FLE (Fluorescent Light Energy) technology, which includes the Kleresca® brand for dermatology conditions (Acne, Rosacea, Skin Rejuvenation) and Lumixa for aesthetic conditions (Skin Normaliser, Collagen Booster). The company also offers LumiHeal® for wound care using Fluorescence Biomodulation, and Dermohemp (CBD-based treatments) is forthcoming. The core Kleresca® FLE platform consists of a patented multi-LED light device and photoconverter gel that converts blue light into fluorescent light energy to stimulate the skin's own repair mechanisms.

Differentiator

Problem solved

Functional benefit

Brands

• Kleresca: FLE (Fluorescent Light Energy) treatments for dermatology conditions including acne, rosacea, and skin rejuvenation. Kleresca is the company's primary brand for therapeutic treatments.
• Lumixa
• LumiHeal
• Dermohemp

Products and services

• Kleresca Acne Treatment FLE-based in-clinic treatment for active acne and acne scarring. Stimulates the skin's own repair mechanisms through fluorescent light energy delivered via LED and photoconverter gel. Designed for dermatology clinics treating moderate to severe acne.
• Kleresca Rosacea Treatment FLE-based treatment reducing pimples, redness, and flushing associated with rosacea. Delivered via Kleresca LED light and photoconverter gel for dermatology clinics.
• Kleresca Skin Rejuvenation Non-destructive FLE treatment stimulating collagen production (up to 400% increase) and improving skin texture, pore size, and fine lines. For dermatology and aesthetic clinics offering rejuvenation procedures.
• Lumixa Skin Normaliser Phototherapy system using FLE to target signs and symptoms of inflammageing. Designed for all skin types to address dehydrated, reactive, or dull skin. For aesthetic clinics.
• Lumixa Collagen Booster Phototherapy system using FLE to target chronoageing or intrinsic ageing. Corrective treatment for ages 35 and above addressing loss of density, fine lines, and open pores. For aesthetic clinics.
• LumiHeal Wound Care System Wound care solution using Fluorescence Biomodulation, delivering fluorescence at cellular level to address all three phases of wound healing (Inflammation, Proliferation, Remodeling). Includes Light Absorbing Molecule (LAM) topical gel activated by LED Activator device (hospital/clinic and portable handheld versions). CE-marked in Europe for chronic wounds including diabetic foot ulcers, venous leg ulcers, and surgical wounds.

Quantifiable outcome

• Up to 400% increase in collagen production with Kleresca Skin Rejuvenation
• +5 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor and core.

• TiME agencyminorImplementation/ SI/ Consulting PartnerWeb design and marketing agency responsible for FB Dermatology's website design and digital marketing.
• FB Magazine ContributorsminorOthersPatient ambassadors and skin activists who contribute to FB Magazine content, sharing treatment experiences and skin positivity messages.
• FB Research GroupcoreStrategic or Co-development PartnerFB Dermatology is part of FB Research Group, a pharmaceutical holding company active in several therapeutic areas. Parent company providing strategic direction and resources.

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Omnilux: Omnilux is a leading LED photobiomodulation brand offering clinical and at-home devices for acne, skin rejuvenation, and wound healing. Directly comparable to FB Dermatology's FLE technology in mechanism category (LED-based dermatology) and target indications (acne, rejuvenation), making it the closest like-for-like competitor.
• Celluma Light Therapy: Celluma manufactures FDA-cleared LED therapy devices for acne, aging, and pain/wound indications sold to dermatology clinics and medspas. Comparable to FB Dermatology as an LED-based phototherapy device company targeting overlapping indications (acne, rejuvenation) via similar clinic channel.
• LightStim: LightStim produces professional and at-home LED light therapy devices for wrinkles, acne, and pain. Directly overlaps FB Dermatology's Kleresca and LumiHeal in mechanism (LED photobiomodulation) and indication mix, serving the same dermatology and aesthetic clinic segment.
• Biofrontera: Biofrontera is a dermatology specialty company commercializing photodynamic therapy (Ameluz) combined with a proprietary red-light lamp for actinic keratosis and field therapy. Directly comparable to FB Dermatology as a light-plus-topical-agent dermatology treatment system sold to clinics.

Broad incumbents

• Lumenis: Lumenis is a global leader in energy-based medical and aesthetic devices, including IPL and laser systems used by dermatologists for acne, rosacea, and rejuvenation. Comparable to FB Dermatology as a broad energy-based dermatology equipment provider, though Lumenis specializes in laser/IPL rather than fluorescent light energy.
• Cutera: Cutera manufactures aesthetic laser and energy-based devices (e.g., AviClear, excel V, enlighten) for dermatology practices and medspas. Comparable to FB Dermatology as an energy-based device company serving dermatology/aesthetic clinics with treatment-system-plus-consumables economics.
• Alma Lasers: Alma Lasers, a Sisram Medical company, offers a broad portfolio of aesthetic and surgical energy-based devices including laser, IPL, RF, and ultrasound platforms. Overlaps with FB Dermatology as a multi-platform energy-based aesthetics/dermatology device vendor with global clinic distribution.
• Sciton: Sciton produces laser and light-based platforms (BBL, Halo, mJOULE) used by dermatologists and plastic surgeons for skin rejuvenation, pigmentation, and acne. Comparable to FB Dermatology as a clinic-channel energy/light-based dermatology device maker with recurring consumables.
• Solta Medical: Solta Medical (Bausch Health) markets Fraxel, Clear + Brilliant, Thermage, and Liposonix energy-based aesthetic devices. Comparable to FB Dermatology as an established energy/light-based dermatology and aesthetics device vendor with global clinic footprint and consumable model.
• Galderma: Galderma is a global dermatology leader offering prescription and aesthetic products (acne, rosacea, skin rejuvenation, wound care) including devices and topicals. Comparable to FB Dermatology as a broad incumbent in the same therapeutic categories (acne, rosacea, skin aging) with both clinic and consumer reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/FBDermatology
• Instagraminstagram.com/fbdermatology
• LinkedInlinkedin.com/company/fbdermatology

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FB Dermatology